drugset / Trial / NCT01036854

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

NCT01036854

Phase 1 Completed 128 enrolled Forest Laboratories
RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of the study is to assess blood levels of ondansetron (EUR1025 24 mg) dose and Zofran 8 mg dose after single and multiple doses are given when taken with a meal and taken on an empty stomach.

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 8 mg Oral
Subject Ondansetron Other / unclassified 16 mg Oral
Subject Ondansetron Other / unclassified 24 mg Oral

Indications

No indication recorded.